Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.56 |
| ▸ | GABRD | O14764 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.56 |
| ▸ | GABRE | P78334 | 1/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8883876 | 1.00 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8883468 | 1.00 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3289711 | 1.00 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8883874 | 1.00 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8883843 | 0.90 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3287608 | 0.87 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8883253 | 0.87 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9124178 | 0.87 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7595107 | 0.85 | RAB9A (0.49) | CCKBRALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL8882750 | 0.84 | GABRP (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-17 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-7053084-B1 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2002099388-A2 | BENZODIAZEPINE BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| EP-0730455-A4 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO INC (US) | 1998-02-04 | — | — | EP | disclosed |
| US-5696110-A | ANTIULCER AGENTS | MERCK, SHARP & DOHME, LTD. (GB) | 1997-12-09 | — | — | US | disclosed |
| EP-0730455-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5438055-A | Antiarrhythmic benzodiazepines | MERCK & CO., INC. (US) | 1995-08-01 | — | — | US | disclosed |
| WO-1995014473-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0609306-A1 | BENZODIAZEPINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF CHOLECYSTOKININ AND/OR GASTRIN RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1994-08-10 | — | — | EP | disclosed |
| WO-1993008176-A1 | BENZODIAZEPINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF CHOLECYSTOKININ AND/OR GASTRIN RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1993-04-29 | — | — | WO | disclosed |
| EP-0539170-A1 | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors | MERCK SHARP & DOHME LTD. (GB) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | PSEN1, APP, GABRA6 | GABRP 14/4885GABRD 12/4885GABRA1 8/4885 |
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | BACE1, APP, APH1B | GABRP 47/4885GABRD 65/4885GABRA1 135/4885 |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | GABRA5, APP, GABRE | GABRP 8/4885GABRD 16/4885GABRA1 4/4885 |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, GABRE | GABRP 6/4885GABRD 15/4885GABRA1 8/4885 |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | BACE1, APP, GABRE | GABRP 6/4885GABRD 15/4885GABRA1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.